We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells

This study is currently recruiting participants.
Verified August 2017 by Benjamin Reubinoff, Hadassah Medical Organization
Sponsor:
ClinicalTrials.gov Identifier:
NCT00801333
First Posted: December 3, 2008
Last Update Posted: August 29, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Benjamin Reubinoff, Hadassah Medical Organization
  Purpose

Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.

The major goal of the project is to develop human iPS cells from various types of cell cultures or lines from existing collections. The IPS cells will be developed for modeling diseases, for developing the technology that may eventually allow the use of IPS cells for transplantation therapy, and for basic research.


Condition
Amyotrophic Lateral Sclerosis

Study Type: Observational
Study Design: Observational Model: Other
Time Perspective: Prospective
Official Title: Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells

Resource links provided by NLM:


Further study details as provided by Benjamin Reubinoff, Hadassah Medical Organization:

Estimated Enrollment: 25
Study Start Date: November 2008
Estimated Study Completion Date: December 2025
Estimated Primary Completion Date: December 2025 (Final data collection date for primary outcome measure)
Detailed Description:

The potential to reprogram somatic cells into an embryonic state raises multiple basic research questions related both to the process of reprogramming and the properties of iPS cells. We will use various approaches to study the molecular mechanisms and processes that occur during reprogramming. We will use various experimental systems to characterize and study the properties of the iPS cells, their biology, developmental potential, capability to give rise to functional differentiated progeny etc.

We will induce the differentiation of the iPS cells towards specific cell lineages and the progeny can be used to study the pathogenesis of diseases. They will be used for developing new therapeutic approaches and for high throughput screening of factors for potential toxic or therapeutic effects.

All samples will be non-identified.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
We will use human somatic cells from existing collections.
Criteria

Inclusion Criteria:

  • Volunteers
  • Male and Female

Exclusion Criteria:

  • Below the official age of consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00801333


Contacts
Contact: Benjamin E. Reubinoff, M.D. PhD. 011-972-2-677-4569 benjaminr@ekmd.huji.ac.il

Locations
Israel
Hadassah Medical Organization - Ein Kerem Campus Recruiting
Jerusalem, Israel, 91120
Contact: Hadas Lemberg, PhD    011-972-2-677-6095    Lhadas@hadassah.org.il   
Sponsors and Collaborators
Hadassah Medical Organization
  More Information

Publications:
Responsible Party: Benjamin Reubinoff, Professor, Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00801333     History of Changes
Other Study ID Numbers: 0511-08-HMO
First Submitted: December 2, 2008
First Posted: December 3, 2008
Last Update Posted: August 29, 2017
Last Verified: August 2017

Keywords provided by Benjamin Reubinoff, Hadassah Medical Organization:
ALS

Additional relevant MeSH terms:
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases